Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Julphar
Covington
Baxter
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Chubb
Medtronic
Chinese Patent Office

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 085789

« Back to Dashboard

NDA 085789 describes TRIFLUOPERAZINE HYDROCHLORIDE, which is a drug marketed by Sandoz, Wockhardt, Duramed Pharms Barr, Ivax Pharms, Mylan, and Watson Labs, and is included in twenty NDAs. It is available from eight suppliers. Additional details are available on the TRIFLUOPERAZINE HYDROCHLORIDE profile page.

The generic ingredient in TRIFLUOPERAZINE HYDROCHLORIDE is trifluoperazine hydrochloride. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the trifluoperazine hydrochloride profile page.
Summary for 085789
Tradename:TRIFLUOPERAZINE HYDROCHLORIDE
Applicant:Sandoz
Ingredient:trifluoperazine hydrochloride
Patents:0
Therapeutic Class:Antipsychotics
Formulation / Manufacturing:see details
Pharmacology for NDA: 085789
Ingredient-typePhenothiazines
Medical Subject Heading (MeSH) Categories for 085789
Suppliers and Packaging for NDA: 085789
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIFLUOPERAZINE HYDROCHLORIDE trifluoperazine hydrochloride TABLET;ORAL 085789 ANDA Sandoz Inc 0781-1034 0781-1034-05 500 TABLET, FILM COATED in 1 BOTTLE (0781-1034-05)
TRIFLUOPERAZINE HYDROCHLORIDE trifluoperazine hydrochloride TABLET;ORAL 085789 ANDA Sandoz Inc 0781-1034 0781-1034-01 100 TABLET, FILM COATED in 1 BOTTLE (0781-1034-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Deloitte
AstraZeneca
QuintilesIMS
Cantor Fitzgerald
Chinese Patent Office
Citi
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot